Research programme: pain therapy - Arakis/Penwest
Latest Information Update: 23 Jan 2004
At a glance
- Originator Penwest Pharmaceuticals; Sosei R&D
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 23 Jan 2004 Discontinued - Preclinical for Pain in USA (PO)
- 29 Nov 2001 Preclinical development for Pain in USA (PO)